What type of cancer does Sotolaxib (AMG510) treat?

Sotorracib (AMG510) is a targeted inhibitor used to treat a specific type of tumor, advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations. KRAS G12C mutation is one of the most common mutation types in NSCLC, accounting for approximately 11% to 13% of NSCLC patients. For this group of patients, traditional chemotherapy and radiotherapy have limited therapeutic effects, so more effective treatment options need to be found.

Sotorasiib is a drug that targets the KRAS G12C mutation. By inhibiting the activity of this mutant, it blocks the signaling pathways for tumor cell proliferation and survival, thereby inhibiting the growth and spread of tumors. Therefore, it shows potential efficacy in helping to control NSCLC with KRAS G12C mutations.

Clinical trials have shown that sotorasiib has demonstrated significant anti-tumor activity in the treatment of patients with advanced NSCLC harboring KRAS G12C mutations, and produced durable clinical responses in some patients. This provides new treatment options for patients who have failed previous treatments or are intolerant to other treatments.

However, it is worth noting that sotorasiib is currently only approved for the treatment of NSCLC withKRAS G12C mutations, and has not yet undergone sufficient clinical trials and approval for other types of cancer. For other types of cancer, further research and clinical trials are still needed to evaluate the efficacy and safety of sotoraxib.

In summary, sotorasiib (AMG510) is a drug targeting the KRAS G12C mutation and is used to treat advanced non-small cell lung cancer with this mutation. It provides a new treatment option for patients who have failed previous treatments or cannot tolerate other treatments, providing hope for improving patients' survival and quality of life.